Table 5.

Summary of Serious Treatment-Emergent Adverse Events in Open-Label Extension

n (%)	PP3M/PP6M n = 57	PP6M/PP6M n = 121	Total N = 178
≥1 Serious TEAEs	2 (3.5)	6 (5.0)	8 (4.5)
Schizophrenia	1 (1.8)	3 (2.5)	4 (2.2)
Psychiatric symptom	0	1 (0.8)	1 (0.6)
Hallucination, auditory	1 (1.8)	0	1 (0.6)
Colon cancer	0	1 (0.8)	1 (0.6)
Metastases to peritoneum	0	1 (0.8)	1 (0.6)
Nephrotic syndrome	0	1 (0.8)	1 (0.6)

Abbreviations: PP3M, paliperidone palmitate 3-month formulation; PP6M, paliperidone palmitate 6-month formulation; TEAE, treatment-emergent adverse event.